TREANDA
Total Payments
$3.3M
Transactions
292
Doctors
120
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $92,869 | 2 | 0 |
| 2023 | $282,321 | 4 | 0 |
| 2022 | $178,308 | 3 | 0 |
| 2021 | $564,659 | 7 | 1 |
| 2020 | $468,940 | 27 | 22 |
| 2019 | $1.7M | 35 | 16 |
| 2018 | $1,176 | 69 | 47 |
| 2017 | $4,438 | 145 | 74 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.3M | 29 | 99.7% |
| Consulting Fee | $3,856 | 5 | 0.1% |
| Food and Beverage | $3,731 | 254 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $750.00 | 4 | 0.0% |
Payments by Type
Research
$3.3M
29 transactions
General
$8,337
263 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Bendamustine, Fludarabine, And Rituximab Conditioning For Haploidentical Stem Cell Transplantation With CD56-Enriched Donor Cell Infusion For Relapsed/Refractory Lymphoma, Multiple Myeloma, and CLL | Teva Pharmaceuticals USA, Inc. | $1.5M | 0 |
| Randomized trial of bendamustine plus rituximab versus pentostatin plus rituximab for relapsed or refractory hairy cell leukemia | Teva Pharmaceuticals USA, Inc. | $534,924 | 0 |
| Pilot Study of Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | Teva Pharmaceuticals USA, Inc. | $434,626 | 0 |
| cHOD17 | Teva Pharmaceuticals USA, Inc. | $303,124 | 0 |
| Bendamustine, fludarabine, and rituximab conditioning for haploidentical stem cell transplantation for relapsed/refractory lymphoma | Teva Pharmaceuticals USA, Inc. | $297,180 | 0 |
| Bendamustine, fludarabine, and rituximab conditioning for haploidentical stem cell transplantation for relapsed/refractory lymphoma_ | Teva Pharmaceuticals USA, Inc. | $133,731 | 0 |
| High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma. | Teva Pharmaceuticals USA, Inc. | $118,872 | 0 |
Top Doctors Receiving Payments for TREANDA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $3.3M | 29 |
| , MD | Medical Oncology | Plano, TX | $2,000 | 1 |
| , D.O | Hematology & Oncology | Lakewood, CA | $651.56 | 2 |
| , MD | Hematology & Oncology | Greenville, SC | $651.56 | 2 |
| , MD | Hematology & Oncology | Wichita, KS | $651.56 | 2 |
| , D.O | Hematology & Oncology | Dallas, TX | $651.56 | 2 |
| , M.D | Hematology & Oncology | Durham, NC | $141.74 | 2 |
| , M.D | Medical Oncology | Charleston, SC | $125.79 | 9 |
| , MD | Hematology & Oncology | Sumter, SC | $122.03 | 8 |
| , M.D | Hematology | Durham, NC | $113.18 | 1 |
| , M.D | Hematology & Oncology | Westwood, NJ | $110.16 | 7 |
| , M.D | Hematology & Oncology | Charleston, SC | $101.02 | 7 |
| , D.O | Hematology & Oncology | Sparta, NJ | $99.51 | 7 |
| , MD | Hematology & Oncology | Port Royal, SC | $97.87 | 7 |
| , M.D | Internal Medicine | Sparta, NJ | $85.19 | 6 |
| , M.D | Medical Oncology | Westwood, NJ | $76.50 | 5 |
| , MD | Hematology & Oncology | Charleston, SC | $75.11 | 5 |
| , MD | Hematology & Oncology | Wayne, NJ | $72.30 | 5 |
| , M.D | Hematology & Oncology | Cooperstown, NY | $71.94 | 4 |
| , M.D | Hematology & Oncology | Charleston, SC | $67.02 | 5 |
| , MD | Medical Oncology | Orangeburg, SC | $62.34 | 5 |
| , M.D | Specialist | Englewood, NJ | $59.16 | 4 |
| , M.D | Hematology & Oncology | Charleston, SC | $55.76 | 4 |
| , M.D | Hematology & Oncology | Mountain Lakes, NJ | $54.84 | 4 |
| , M.D | Hematology & Oncology | Mountain Lakes, NJ | $54.84 | 4 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.3M
- Total Doctors 120
- Transactions 292
About TREANDA
TREANDA is a drug associated with $3.3M in payments to 120 healthcare providers, recorded across 292 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2024. In 2024, $92,869 was paid across 2 transactions to 0 doctors.
The most common payment nature for TREANDA is "Unspecified" ($3.3M, 99.7% of total).
TREANDA is associated with 7 research studies, including "Bendamustine, Fludarabine, And Rituximab Conditioning For Haploidentical Stem Cell Transplantation With CD56-Enriched Donor Cell Infusion For Relapsed/Refractory Lymphoma, Multiple Myeloma, and CLL" ($1.5M).